Focused On-demand Library for Thyroid receptor-interacting protein 11

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q15643

UPID:
TRIPB_HUMAN

ALTERNATIVE NAMES:
Clonal evolution-related gene on chromosome 14 protein; Golgi-associated microtubule-binding protein 210; Trip230

ALTERNATIVE UPACC:
Q15643; B2RUT2; O14689; O15154; O95949; Q6MZL5

BACKGROUND:
The protein Thyroid receptor-interacting protein 11, with alternative names including Clonal evolution-related gene on chromosome 14 protein, is essential for maintaining Golgi structure and function. It supports efficient trafficking within the early secretory pathway and binds to the thyroid receptor's ligand binding domain, enhancing THRB-modulated transcription.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in conditions like Achondrogenesis 1A, characterized by severe skeletal malformations, and Odontochondrodysplasia 1, understanding Thyroid receptor-interacting protein 11's role could lead to novel therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 979 of 8789